BioXcel股价在完成关键第三阶段试验后飙升

英为财情
Aug 01, 2025

Investing.com -- BioXcel Therapeutics Inc (NASDAQ:BTAI)股价在宣布完成其IGALMI®(右美托咪啶)关键性第三阶段SERENITY居家临床试验后跳升23.7%。 这家利用人工智能开发神经科学药物的生物制药公司报告称,该研究已完成最后一位患者访视,该研究评估IGALMI用于治疗居家环境中与双相情感障碍或精神分裂症相关的激动状态。预计本月将发布...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10